Engflag
Advertisements

Insulina Basaglar

Quick links to important sections

Insulina Basaglar

Insulina Basaglar_EN
Advertisements
Advertisements

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Insulina Basaglar

Quick Facts

Property Description
Active Ingredient Insulin Glargine
Form Solution for injection (in prefilled pen)
Pharmacological Class Long-acting basal insulin / Antidiabetic Agent
Common Use Maintaining sustained blood glucose regulation
Origin Synthetic human insulin analog (recombinant DNA)

What Type of Medicine is Insulina Basaglar and Its Core Classification?

Insulina Basaglar is a prescription-only antidiabetic agent and is classified as a long-acting basal insulin. This medicine's primary function is to serve as a sustained blood glucose regulator by providing the body with a continuous, low level of background insulin throughout the day and night. It is administered as a sterile solution for injection via the subcutaneous route, commonly utilizing a prefilled pen delivery device such as the KwikPen.

The Insulin Glargine active ingredient is recognized as a recombinant human insulin analog, meaning it is manufactured through genetic engineering to possess a modified structure for a prolonged release profile. This classification supports its role as a foundational therapy for glucose management due to its consistent action.

Composition and Origin: Insulin Glargine's Unique Profile

Insulina Basaglar utilizes a solution containing Insulin Glargine. This long-acting basal profile is achieved because the acidic solution forms micro-precipitates upon injection into the subcutaneous tissue. These depots dissolve slowly, releasing the active ingredient consistently over approximately 24 hours.

This sustained delivery is key to creating a “peakless” action profile, a distinguishing feature that minimizes blood sugar variability and supports metabolic needs during periods of fasting, which is a critical aspect of basal insulin function.

Primary Purpose of Basal Insulin Therapy

By delivering a constant, predictable level of insulin, the overall purpose of Insulina Basaglar is to replace the necessary foundational insulin signaling that is deficient in diabetes mellitus. The medication helps establish glucose homeostasis by facilitating the uptake of glucose by peripheral tissues and suppressing excessive glucose production by the liver. This continuous metabolic support is essential for achieving and maintaining euglycemia, which refers to a normal concentration of sugar in the blood.

Regulatory References

  1. MedlinePlus, Insulina Glargine Information
  2. NIDDK, Insulin Fact Sheet
Advertisements

What side effects are possible with Insulina Basaglar?

Possible Side Effects and Safety Information

The safety profile of Insulina Basaglar (Insulin Glargine) is primarily defined by the risk of low blood sugar. All documented adverse reactions and safety statements are based strictly on official regulatory prescribing information from governmental health authorities.

Frequency-Classified Adverse Reactions

The most frequent adverse effect classified in regulatory documents is hypoglycaemia (low blood sugar), which is designated as Very Common, affecting more than 1 in 10 patients. This is the principal safety consideration with all insulins.

Other adverse effects are classified by the following System-Organ Classes:

  • Common (affecting 1 in 10 to 1 in 100 patients): Includes Injection Site Reactions (such as pain or swelling), Lipohypertrophy (skin thickening), Peripheral Edema (fluid retention), and Weight Gain.
  • Rare (affecting fewer than 1 in 1,000 patients): Includes Systemic Allergic Reactions, which are considered serious and may involve widespread symptoms like bronchospasm.

Serious Adverse Reactions and Safety Constraints

Severe hypoglycaemia is a documented serious adverse reaction, with the potential to be life-threatening. The regulatory profile also isolates Systemic Allergic Reactions and potential Hypokalemia (low potassium) as serious concerns.

Safety notes specify that Lipodystrophy is associated with the long-term use of insulin. The worsening of diabetic retinopathy or the onset of peripheral edema are time-related patterns associated with the initial intensification or rapid improvement in metabolic control.

Administration-agnostic constraints state that Insulina Basaglar is not recommended for the treatment of acute Diabetic Ketoacidosis (DKA). Furthermore, use with certain oral antidiabetic agents (Thiazolidinediones) carries a specific safety consequence related to potential fluid retention.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Overdosage with Insulina Basaglar results exclusively in hypoglycemia (low blood glucose), which is the only documented clinical consequence. The severity of the overdose is directly proportional to the degree and duration of this low blood sugar event. Manifestations typically range from mild symptoms such as drowsiness, tremors, and confusion to severe, potentially life-threatening outcomes.

The most serious clinical manifestations documented in regulatory labeling include seizures and complete loss of consciousness. Due to the long-acting pharmacological profile of Insulin Glargine, an overdose carries the specific risk of prolonged hypoglycemia, which may necessitate extended observation.

Mandatory Emergency Actions

Regulatory authorities require that you seek immediate medical attention for any suspected overdose. It is mandated to contact emergency services immediately if the overdose leads to severe symptoms like loss of consciousness or seizures.

Supportive Procedures

No specific antidote is known for this overdose. Management procedures described in official labels focus on counteracting the low blood sugar effect. Mild episodes require the administration of oral carbohydrates. Severe episodes require medical intervention involving glucagon or concentrated intravenous glucose. Because of the risk of prolonged effect, hospital monitoring may be required for stabilization, particularly in patients with pre-existing conditions like renal or hepatic impairment.

Advertisements

Therapeutic Uses of Insulina Basaglar

What Insulina Basaglar Treats: Main Uses and Benefits

Insulina Basaglar is considered relevant in the therapeutic management of blood sugar levels. This medication is applied in the therapeutic domain of Type 1 diabetes and Type 2 diabetes.

Insulina Basaglar is commonly used as a foundational component for the lifelong management of Type 1 diabetes mellitus and Type 2 diabetes mellitus in adults, and for Type 1 diabetes in children 6 years of age and older. It addresses the clinical situation where patients require replacement of the basal (background) insulin to address symptoms related to systemic imbalance, such as chronically elevated blood sugar levels (hyperglycemia), and is applied in addressing symptoms that interfere with daily functioning, such as unstable blood sugar levels between meals and overnight.

It supports functional stability, which may assist with maintaining a sense of stability during periods of heightened systemic burden.

“Basal insulin therapy supports general well-being during symptomatic phases and is commonly used to help with managing the overall risk of long-term complications.”

Quick Fact: Management for Persistent Hyperglycemia

Feature Description
Symptom Domain Symptoms related to physical discomfort, particularly elevated Fasting Plasma Glucose (FPG).
Clinical Context Foundational basal replacement therapy; adjunct to mealtime insulin/oral agents.
Primary Therapeutic Benefit Provides continuous, stable background insulin to promote metabolic consistency.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Insulina Basaglar?

The official regulatory profile defines specific populations for whom the use of Insulina Basaglar is permitted, restricted, or prohibited. The medicine is indicated for use in adults with both Type 1 and Type 2 diabetes mellitus, and in pediatric patients 6 years of age and older who have Type 1 diabetes. Use in children under six years old with Type 1 diabetes or in children of any age with Type 2 diabetes has not had safety and effectiveness established by regulators.

Insulina Basaglar is strictly contraindicated for use during episodes of active hypoglycemia (low blood sugar) or in patients with a known hypersensitivity to insulin glargine or any of its inactive ingredients. The medicine is also not recommended for the acute management of diabetic ketoacidosis (DKA).

For populations with existing conditions, regulators advise caution: patients with renal (kidney) or hepatic (liver) impairment may require close monitoring due to potentially diminished insulin requirements. Use during pregnancy is permitted only after a risk-benefit assessment confirms the potential benefit justifies the potential risk to the fetus. Lactation requires caution, as it is unknown whether the active ingredient is excreted in human milk.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Insulina Basaglar is a long-acting insulin, and its blood-glucose-lowering effect can be altered by concomitant medicinal products, leading to a risk of either hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar). These interactions are primarily pharmacodynamic in nature, affecting the body's glucose balance.

Products that may enhance the effect:

Concomitant use with certain medicines may potentiate the effect of insulin, increasing the risk of hypoglycemia. These include oral antidiabetic products, ACE inhibitors, salicylates, fibrates, MAO inhibitors, and somatostatin analogues.

Products that may reduce the effect:

Other medicinal products can reduce the blood-glucose-lowering effect, increasing the risk of hyperglycemia. These include corticosteroids, danazol, diuretics, thyroid hormones, growth hormone, and certain atypical antipsychotics (e.g., olanzapine, clozapine).

Other Significant Interactions

  • Masking of Hypoglycemia Symptoms: Sympatholytic medicinal products, such as beta-blockers, may reduce or completely mask the typical warning signs of low blood sugar (e.g., tremor and sweating).
  • Pioglitazone: The combination with pioglitazone must be used with caution and patient monitoring, as cases of heart failure have been reported.
  • Alcohol: Alcohol may potentiate or weaken the blood-glucose-lowering effect of insulin.
  • Restrictions: Basaglar must not be mixed with any other insulin or diluted, as this alters its intended time-action profile.
Advertisements

Mechanism of Action

Insulina Basaglar is the long-acting insulin analog, glargine. Upon subcutaneous injection, the acidic formulation (pH 4.0) is neutralized by the physiological environment, which causes the formation of micro-precipitates at the injection site.

These micro-precipitates slowly dissolve, gradually releasing insulin hexamers that subsequently dissociate into active insulin monomers. These monomers bind to the insulin receptor (IR) on the membranes of target cells (hepatocytes, adipocytes, and skeletal muscle cells), initiating the intracellular signaling cascade. This binding promotes the translocation of the Glucose Transporter type 4 (GLUT4) from the cytoplasm to the cell membrane, thereby increasing the rate of glucose transport into these tissues.

This intracellular signaling suppresses hepatic glucose production (specifically gluconeogenesis and glycogenolysis) and promotes the uptake of circulating glucose in peripheral tissues. The sustained rate of monomer release contributes to a prolonged duration of action.

Advertisements

Dosage and Administration Information

How to Use Insulina Basaglar: Official Administration Guidelines

Basaglar (insulin glargine) must be administered once daily by subcutaneous injection (under the skin) and should be taken at the same time every day to ensure consistent, long-acting insulin effect, irrespective of meal timing.

Administration Requirements

Procedural Domain Official Requirement
Route & Timing Inject subcutaneously once daily at the same time every day.
Dosing The dosage is individualized based on the patient's metabolic needs, blood glucose monitoring results, and glycemic goal. Adjustments should be made only under medical supervision.
Preparation Do not dilute or mix Basaglar with any other insulin or solution. The solution must be clear and colorless with no visible particles before use.
Injection Sites Administer into the abdominal area, thigh, or deltoid. Injection sites must be rotated within the same general region from one injection to the next to reduce the risk of lipodystrophy.
Age Groups Approved for use in adults and pediatric patients with diabetes mellitus.

Missed Dose Instructions

If a dose of Basaglar is missed, the patient should be advised to check their blood glucose level and then resume their once-daily dosing schedule at the next regular dosing time. A double dose must not be injected to make up for a missed dose.

These instructions define the standardized, non-variable procedural components for safely using Basaglar.

Advertisements

Recent Clinical Evidence

Insulina Basaglar: Recent Clinical Evidence

Basaglar is an approved follow-on insulin glargine product used to help manage blood sugar (glucose) levels in adults and children (aged 6 and older) with type 1 diabetes and in adults with type 2 diabetes. The active ingredient, insulin glargine, is a long-acting recombinant human insulin analogue that provides a relatively constant level of glucose-lowering action over approximately 24 hours.

Equivalence and Efficacy Studies

Clinical trials have been conducted to evaluate the effects of Basaglar compared to the reference insulin glargine product. Studies in both insulin-naive and insulin-experienced patients with Type 1 (ELEMENT 1) and Type 2 (ELEMENT 2) diabetes examined key outcomes such as change in glycated hemoglobin ( A1C) levels and safety profiles.

These pivotal trials found that Basaglar provided similar glycemic control compared to the reference product across the studied populations. Specifically, the mean change in A1C from baseline was found to be statistically non-inferior (equivalent) between the two long-acting insulin glargine products.

Safety and Tolerability Research

Research has also explored the safety and tolerability of Basaglar. The overall incidence of adverse events, including the most common side effect—hypoglycemia (low blood sugar)—was generally similar between Basaglar and the reference insulin glargine product in both Type 1 and Type 2 diabetes trials.

Research has also tracked the development of anti-insulin antibodies. While minor differences in antibody formation were sometimes observed, no significant correlation was established between these antibody levels and the clinical endpoints of A1C, insulin dose, or hypoglycemia rates. Other common reported adverse effects in the trials included injection site reactions, infections, and weight gain. Large-scale post-market surveillance continues to monitor the utilization, safety, and effectiveness of this insulin glargine product.

Advertisements

How should Insulina Basaglar be stored and disposed of?

How to Store and Dispose of Insulina Basaglar?

Strict storage and disposal protocols, based on regulatory labeling, are mandatory to maintain product efficacy and safety.

Storage Requirements

Status Temperature Range Maximum Duration
Unopened Refrigerated (2 C to 8 C) Until Expiration Date
Opened (In-Use) Room Temperature (Up to 30 C) 28 Days

Handling & Protection:

  • Do not freeze Basaglar; the product must be discarded if it has been frozen.
  • Protect the pen or cartridge from direct heat and direct light.
  • Visually inspect the solution; do not use it if it is cloudy, colored, or contains particles.
  • Keep the medication out of the reach and sight of children.

Disposal Instructions

  • Needles and Syringes must be placed immediately after use in a puncture-resistant sharps disposal container.
  • Discard any in-use pen that has exceeded the 28-day stability period.
  • Follow local governmental guidelines for the proper disposal of filled sharps containers and expired medication.
Advertisements

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Insulina Basaglar found in:

A-Z Index: